Inhibikase Therapeutics, Inc. (IKT)
2.41
-0.02
(-0.82%)
USD |
NASDAQ |
Sep 09, 13:39
Inhibikase Therapeutics EPS Diluted (Quarterly) : -0.1122 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1122 |
| March 31, 2026 | -0.0951 |
| December 31, 2025 | -0.0967 |
| September 30, 2025 | -0.1325 |
| June 30, 2025 | -0.1102 |
| March 31, 2025 | -0.1528 |
| December 31, 2024 | -0.1749 |
| September 30, 2024 | -0.6505 |
| June 30, 2024 | -0.6582 |
| March 31, 2024 | -0.7333 |
| December 31, 2023 | -0.6754 |
| September 30, 2023 | -0.8602 |
| June 30, 2023 | -1.106 |
| March 31, 2023 | -0.9766 |
| December 31, 2022 | -1.018 |
| September 30, 2022 | -1.069 |
| June 30, 2022 | -1.104 |
| Date | Value |
|---|---|
| March 31, 2022 | -1.105 |
| December 31, 2021 | -1.202 |
| September 30, 2021 | -1.067 |
| June 30, 2021 | -1.292 |
| March 31, 2021 | -1.573 |
| December 31, 2020 | -0.7211 |
| September 30, 2020 | -0.4003 |
| June 30, 2020 | -0.2518 |
| March 31, 2020 | -0.3268 |
| December 31, 2019 | -0.25 |
| September 30, 2019 | -0.7048 |
| June 30, 2019 | -1.363 |
| March 31, 2019 | -1.009 |
| December 31, 2018 | -0.7352 |
| March 31, 2018 | -0.0727 |
| December 31, 2017 | 0.0259 |
| March 31, 2017 | -0.1079 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.59M |
| Total Expenses (Quarterly) | 19.59M |
| Enterprise Value | 161.82M |
| Earnings Yield | -18.11% |
| Normalized Earnings Yield | -18.19 |